Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial.

被引：0
|
作者：
Genovese, Mark C. [1 ]
Covarrubias Cobos, Arturo
Leon, Gustavo [2 ]
Mysler, Eduardo F. [3 ]
Keiserman, Mauro W. [4 ]
Valente, Robert M. [5 ]
Nash, Peter T. [6 ]
Simon Campos, J. Abraham [7 ]
Porawska, Wieslawa [8 ]
Box, Jane H. [9 ]
Legerton, Clarence W., III [10 ]
Nasonov, Evgeny L. [11 ]
Durez, Patrick [12 ]
Pappu, Ramesh [13 ]
Delaet, Ingrid [13 ]
Teng, Julie [13 ]
Alten, Rieke [14 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Inst Ginecol & Reprod, Lima, Peru
[3] OMI, Buenos Aires, DF, Argentina
[4] Pontiphycial Catholic Univ, Porto Alegre, RS, Brazil
[5] Arthrit Ctr Nebraska, Lincoln, NE USA
[6] Univ Queensland, Brisbane, Qld, Australia
[7] Ctr Especialidades Med, Merida, Mexico
[8] Poznanski Osrodek Med Novamed, Poznan, Poland
[9] Box Arthrit & Rheumatol Carolinas, Charlotte, NC USA
[10] LowCountry Rheumatol, Charleston, SC USA
[11] Inst Rheumatol, Moscow, Russia
[12] Catholic Univ Louvain, B-1200 Brussels, Belgium
[13] Bristol Myers Squibb Co, Princeton, NJ USA
[14] Schlosspk Klin, Berlin, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
402
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 12 条
  • [1] SUBCUTANEOUS ABATACEPT VERSUS INTRAVENOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: LONG-TERM DATA FROM THE ACQUIRE TRIAL
    Genovese, Mark C.
    Covarrubias Cobos, Arturo
    Leon, Gustavo
    Mysler, Eduardo F.
    Keiserman, Mauro W.
    Valente, Robert M.
    Nash, Peter T.
    Simon Campos, J. Abraham
    Porawska, Wieslawa
    Box, Jane H.
    Legerton, Clarence W., III
    Nasonov, Evgeny L.
    Durez, Patrick
    Pappu, Ramesh
    Delaet, Ingrid
    Teng, Julie
    Alten, Rieke
    [J]. RHEUMATOLOGY, 2012, 51 : 128 - 129
  • [2] Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders
    Amano, Koichi
    Matsubara, Tsukasa
    Tanaka, Takaaki
    Inoue, Hiroshi
    Iwahashi, Mitsuhiro
    Kanamono, Toshihisa
    Nakano, Teruaki
    Uchimura, Shoichi
    Izumihara, Tomomaro
    Yamazaki, Akira
    Karyekar, Chetan S.
    Takeuchi, Tsutomu
    [J]. MODERN RHEUMATOLOGY, 2015, 25 (05) : 665 - 671
  • [3] A MULTI-CENTER, DOUBLE-DUMMY, DOUBLE-BLIND STUDY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) COMPARED WITH INTRAVENEOUS (IV) ABA IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
    Matsubara, T.
    Inoue, H.
    Iwahashi, M.
    Yamazaki, A.
    Takeuchi, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 197 - 197
  • [4] Abatacept (ABA) slows radiographic progression over 2 yrs in rheumatoid arthritis (RA) patients (Pts) with an inadequate response to methotrexate (MTX): Results from the long-term extension (LTE) of the AIM trial
    Westhovens, R.
    Peterfy, C.
    Vratsanos, G.
    Becker, J. C.
    Aranda, R.
    Teng, J.
    Kremer, J.
    Genant, H. K.
    [J]. RHEUMATOLOGY, 2007, 46 : I15 - I16
  • [5] Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial.
    Fleischmann, Roy
    Weinblatt, Michael E.
    Schiff, Michael H.
    Khanna, Dinesh
    Furst, Daniel
    Maldonado, Michael A.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S578 - S578
  • [6] Abatacept (Aba) provides long-term efficacy and significant sustained benefits in clinical and patient (Pt)-reported outcomes (PROs) through 2 yrs in rheumatoid arthritis (RA) pts with an inadequate response to Methotrexate (MTX): The long-term extension (LTE) of the aim BA in inadequate responders to MTX) trial
    Emery, P.
    Russell, A.
    Becker, J. C.
    Aranda, R.
    Li, T.
    Teng, J.
    Schmidely, N.
    LeBars, M.
    Moreland, L. W.
    Westhovens, R.
    Kremer, J. M.
    [J]. RHEUMATOLOGY, 2007, 46 : I40 - I40
  • [7] Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
    Kremer, Joel M.
    Russell, Anthony S.
    Emery, Paul
    Abud-Mendoza, Carlos
    Szechinski, Jacek
    Westhovens, Rene
    Li, Tracy
    Zhou, Xianhuang
    Becker, Jean-Claude
    Aranda, Richard
    Peterfy, Charles
    Genant, Harry K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (10) : 1826 - 1830
  • [8] 2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naive RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
    Fleischmann, R.
    Weinblatt, M. E.
    Schiff, M.
    Khanna, D.
    Maldonado, M. A.
    Nadkarni, A.
    Furst, D. E.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S183 - S183
  • [9] 2-Year Results from the AMPLE (Abatacept versus Adalimumab Comparison in Biologic-Naive RA Patients with Background Methotrexate) Trial: Changes in Patient-Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis
    Fleischmann, Roy
    Weinblatt, Michael
    Schiff, Michael
    Khanna, Dinesh
    Maldonado, Michael
    Nadkarni, Anagha
    Furst, Daniel
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1475 - 1476
  • [10] Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): Results from the long-term extension (LTE) of the AIM trial
    Genant, H. K.
    Peterfy, C.
    Westhovens, R.
    Becker, J. P.
    Aranda, R.
    Teng, J.
    Kremer, J. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 57 - 58
12